Alzheimer’s patients typically have poor quality sleep, which is thought to contribute to their cognitive impairment. One way to improve quality sleep is by using an FDA approved Alzheimer’s drugs called betaxolene, which acts on cholinesterase enzymes. Alzheimer’s patients have shown improvement in short term memory and concentration with the use of betaxolene. There are several studies being performed on the effects of taking betaxolene and the results are expected to be available within few years. Based on the results of these studies, if the studies confirm the efficacy of Memantine in improving cognitive function, it will be difficult for the distributor to obtain the rights to distribute the drug in the United States and in other developed countries where it may prove useful to those suffering from the debilitating effects of Alzheimer’s.
Request Here For PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1373
The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is projected to exhibit a CAGR of 9.5% over the forecast period (2017 – 2025).
Global Alzheimer’s Drugs Market: Drivers
R&D of new drugs is expected to propel growth of the global Alzheimer’s drugs market over the forecast period. For instance, in 2017, Genentech partnered with AC Immune for R&D of crenezumab, anti-amyloid beta antibody.
Global Alzheimer’s Drugs Market: Opportunities
R&D of new drugs is expected to offer lucrative growth opportunities for players in the global Alzheimer’s drugs market. For instance, in 2017, TauRx Therapeutics announced phase three results of investigational drug LMTX first tau aggregation inhibitor in Alzheimer’s disease.
Market Trends
North America is expected to witness significant growth in the global Alzheimer’s drugs market, owing to new guidelines for the treatment of Alzheimer’s disease. For instance, in January 2018, the U.S Food and Drug Administration proposed new guidelines for the treatment of earlier-stage Alzheimer’s patients who have not yet showed functional disability or clinical abnormality. The guidelines were aimed at lowering the clinical study goals and expand access to safe and effective treatment options.
Major players in the global Alzheimer’s drugs market are focused on adopting merger and acquisition strategies to expand their product portfolio. For instance, in 2016, Merck acquired exclusive worldwide license for R&D of an investigational, preclinical anti-tau antibody from Japan-based Teijin Pharma.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/1373
Covid-19 Impact Analysis
Emergence of Covid-19 has led to free virtual education programs and online support groups in the Alzheimer’s drugs market. In April 2020, The Alzheimer’s Association announced to offer free virtual education programs and online support groups to caregivers, Alzheimer’s patients, and their families.
Global Alzheimer’s Drugs Market: Competitive Landscape
Major players operating in the global Alzheimer’s drugs market include, AstraZeneca plc, and AC Immune, Eli Lilly and Company, Eisai Co. Ltd., Hoffman-La Roche Ltd., Janssen Pharmaceutical, Lundbeck A/S, Novartis International AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., TauRx Pharmaceuticals Ltd, and VTV Therapeutics.
Global Alzheimer’s Drugs Market: Key Developments
Major players in the global Alzheimer’s drugs market are focused on adopting merger and acquisition strategies to expand their product portfolio. For instance, in 2016, Teva Pharmaceutical Industries Ltd. acquired the Actavis Generics from Allergan. The US$ 40 billion acquisition includes Actavis Generics’ Alzheimer’s portfolio.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/1373
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Alzheimer’s Drugs Market Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Alzheimer’s Drugs Market Industry Impact
Chapter 2 Global Alzheimer’s Drugs Market Competition by Types, Applications, and Top Regions and Countries
2.1 Global Alzheimer’s Drugs Market (Volume and Value) by Type
2.3 Global Alzheimer’s Drugs Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Alzheimer’s Drugs Market Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Alzheimer’s Drugs Market Analysis
Chapter 6 East Asia Alzheimer’s Drugs Market Analysis
Chapter 7 Europe Alzheimer’s Drugs Market Analysis
Chapter 8 South Asia Alzheimer’s Drugs Market Analysis
Chapter 9 Southeast Asia Alzheimer’s Drugs Market Analysis
Chapter 10 Middle East Alzheimer’s Drugs Market Analysis
Chapter 11 Africa Alzheimer’s Drugs Market Analysis
Chapter 12 Oceania Alzheimer’s Drugs Market Analysis
Chapter 13 South America Alzheimer’s Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Alzheimer’s Drugs Market Business
Chapter 15 Global Alzheimer’s Drugs Market Market Forecast (2022-20278
Chapter 16 Conclusions
Research Methodology
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837